GAS6 and neoplasm: If the GAS6/AXL axis is also involved in chemoresistance in ovarian cancer, targeting this pathway may sensitise tumours to paclitaxel and carboplatin, the current mainstays of therapy, whilst also directly inhibiting tumour growth.